Cite
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
MLA
Schwartz, G. G., et al. “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.” New England Journal of Medicine, vol. 379, no. 22, Nov. 2018, pp. 2097–107. EBSCOhost, https://doi.org/10.1056/NEJMoa1801174.
APA
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., & Tricoci, P. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 379(22), 2097–2107. https://doi.org/10.1056/NEJMoa1801174
Chicago
Schwartz, G. G., P. G. Steg, M. Szarek, D. L. Bhatt, V. A. Bittner, R. Diaz, J. M. Edelberg, et al. 2018. “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.” New England Journal of Medicine 379 (22): 2097–2107. doi:10.1056/NEJMoa1801174.